Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene

被引:93
作者
Lossos, A
Meiner, Z
Barash, V
Soffer, D
Schlesinger, I
Abramsky, O
Argov, Z
Shpitzen, S
Meiner, V
机构
[1] Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Neurol, IL-91010 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91010 Jerusalem, Israel
[4] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91010 Jerusalem, Israel
[5] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Med Genet, Ctr Res Prevent & Treatment Atherosclerosis, IL-91010 Jerusalem, Israel
[6] Sapir Med Ctr, Dept Neurol, Kfar Saba, Israel
关键词
D O I
10.1002/ana.410440604
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Adult polyglucosan body disease (APBD) is a late-onset, slowly progressive disorder of the nervous system caused by glycogen branching enzyme (GBE) deficiency in a subgroup of patients of Ashkenazi Jewish origin. Similar biochemical finding is shared by glycogen storage disease type IV (GSD TV) that, in contrast to APBD, is an early childhood disorder with primarily systemic manifestations. Recently, the GEE cDNA was cloned and several mutations were characterized in different clinical forms of GSD IV. To examine whether mutations in the GEE gene account for APBD, we studied 7 patients from five Jewish families of Ashkenazi ancestry. The diagnosis was based on the typical clinical and pathological findings, and supported by reduced GEE activity. We found that the clinical and biochemical APBD phenotype in all five families cosegregated with the Tyr(329)Ser mutation, not detected in 140 controls. As this mutation was previously identified in a nonprogressive form of GSD IV and was shown in expression studies to result in a significant residual GEE activity, present findings explain the late onset and slowly progressive course of APBD in our patients. We conclude that APBD represents an allelic variant of GSD IV, but the reason for the difference in primary tissue involvement must be established.
引用
收藏
页码:867 / 872
页数:6
相关论文
共 32 条
[11]  
Gil-Neciga E, 1995, Neurologia, V10, P167
[12]   ADULT POLYGLUCOSAN BODY DISEASE (APBD) [J].
GRAY, F ;
GHERARDI, R ;
MARSHALL, A ;
JANOTA, I ;
POIRIER, J .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1988, 47 (04) :459-474
[13]   A NEW VARIANT OF TYPE-IV GLYCOGENOSIS - DEFICIENCY OF BRANCHING ENZYME-ACTIVITY WITHOUT APPARENT PROGRESSIVE LIVER-DISEASE [J].
GREENE, HL ;
BROWN, BI ;
MCCLENATHAN, DT ;
AGOSTINI, RM ;
TAYLOR, SR .
HEPATOLOGY, 1988, 8 (02) :302-306
[14]  
KARPATI G, 1983, NEUROLOGY S2, V33, P246
[15]   HEREDITARY BRANCHING ENZYME DYSFUNCTION IN ADULT POLYGLUCOSAN BODY DISEASE - A POSSIBLE METABOLIC CAUSE IN 2 PATIENTS [J].
LOSSOS, A ;
BARASH, V ;
SOFFER, D ;
ARGOV, Z ;
GOMORI, M ;
BENNARIAH, Z ;
ABRAMSKY, O ;
STEINER, I .
ANNALS OF NEUROLOGY, 1991, 30 (05) :655-662
[16]  
LOSSOS A, 1997, 7 AL S NEUR DIS AL H
[17]   Clinical and laboratory findings in four patients with the non-progressive hepatic form of type IV glycogen storage disease [J].
McConkieRosell, A ;
Wilson, C ;
Piccoli, DA ;
Boyle, J ;
DeClue, T ;
Kishnani, P ;
Shen, JJ ;
Boney, A ;
Brown, B ;
Chen, YT .
JOURNAL OF INHERITED METABOLIC DISEASE, 1996, 19 (01) :51-58
[18]   POLYGLUCOSAN BODY DISEASE SIMULATING AMYOTROPHIC-LATERAL-SCLEROSIS [J].
MCDONALD, TD ;
FAUST, PL ;
BRUNO, C ;
DIMAURO, S ;
GOLDMAN, JE .
NEUROLOGY, 1993, 43 (04) :785-790
[19]  
MCMASTER KR, 1979, ARCH PATHOL LAB MED, V103, P105
[20]   JEWISH DISEASES AND ORIGINS [J].
MOTULSKY, AG .
NATURE GENETICS, 1995, 9 (02) :99-101